CLINICAL STUDY: PERCUTANEOUS CORONARY INTERVENTION
Statin treatment following coronary artery stenting and one-year survival
Albert Schömig, MD* ,*,
Julinda Mehilli, MD*,
Heidrun Holle, RN*,
Karin Hösl, RN*,
Dorejd Kastrati*,
J.ürgen Pache, MD ,
Melchior Seyfarth, MD ,
Franz-Josef Neumann, MD ,
Josef Dirschinger, MD and
Adnan Kastrati, MD*
* Deutsches Herzzentrum, Munich, Germany
1. Medizinische Klinik rechts der Isar, Technische Universität, Munich, Germany
Manuscript received November 28, 2001;
revised manuscript received March 26, 2002,
accepted June 4, 2002.
* Reprint requests and correspondence: Dr. Albert Schömig, Deutsches Herzzentrum, Lazarettstr. 36, 80636 München, Germany. aschoemig{at}dhm.mhn.de
OBJECTIVES: We assessed the influence of statin therapy given after the procedure on one-year survival of patients treated with coronary artery stenting.
BACKGROUND: Coronary artery stenting is currently a common treatment option for patients with symptomatic coronary artery disease (CAD). Although several secondary prevention trials have demonstrated improved survival achieved with statin therapy in conservatively treated patients with CAD, it is not known whether this benefit can also be expected in patients undergoing percutaneous coronary interventions with intraluminal stenting.
METHODS: This study included 4,520 patients younger than 80 years who underwent coronary artery stenting and were discharged from the hospital in the period October 1995 through September 1999. We compared one-year mortality of 3,585 patients who received statins after stenting with that of 935 patients who did not.
RESULTS: The mortality rate at one year was 2.6% among patients who received statins and 5.6% among those who did not. Thus, statin therapy at discharge was associated with an unadjusted odds ratio (OR) of 0.46 (95% confidence interval [CI], 0.33 to 0.65), indicating a 54% reduction in the risk of death at one year. After adjusting for other covariates, the risk reduction associated with statin therapy was 49%, OR 0.51 (95% CI, 0.36 to 0.71). This reduction was observable in most of the subgroups of patients.
CONCLUSIONS: The results of this nonrandomized study show that statin therapy improves survival after coronary artery stenting independent of patient characteristics recorded on the day of the intervention.
|
Abbreviations and Acronyms
| | ACE | | angiotensin-converting enzyme | | CAD | | coronary artery disease | | CI | | confidence interval | | LV | | left ventricular | | MI | | myocardial infarction | | OR | | odds ratio | | PCI | | percutaneous coronary intervention | | PTCA | | percutaneous transluminal coronary angioplasty |
|
This article has been cited by other articles:

|
 |

|
 |
 
S. G. Ellis and S. Anwaruddin
Recapturing the Magic: Revisiting the Pleiotropic Effects of Statins in Percutaneous Coronary Revascularization
J. Am. Coll. Cardiol.,
August 4, 2009;
54(6):
566 - 568.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Ndrepepa, S. Braun, K. Niemoller, J. Mehilli, N. von Beckerath, O. von Beckerath, W. Vogt, A. Schomig, and A. Kastrati
Prognostic Value of N-Terminal Pro-Brain Natriuretic Peptide in Patients With Chronic Stable Angina
Circulation,
October 4, 2005;
112(14):
2102 - 2107.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
O. Gorchakova, N. von Beckerath, M. Gawaz, A. Mocz, A. Joost, A. Schomig, and A. Kastrati
Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting
Eur. Heart J.,
November 1, 2004;
25(21):
1898 - 1902.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. J. Vaughan and A. M. Gotto Jr
Update on Statins: 2003
Circulation,
August 17, 2004;
110(7):
886 - 892.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Lange, H. Suryapranata, G. De Luca, C. Borner, J. Dille, K. Kallmayer, M. N. Pasalary, E. Scherer, and J.-H. E. Dambrink
Folate Therapy and In-Stent Restenosis after Coronary Stenting
N. Engl. J. Med.,
June 24, 2004;
350(26):
2673 - 2681.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. C. Herrmann
Prevention of Cardiovascular Events after Percutaneous Coronary Intervention
N. Engl. J. Med.,
June 24, 2004;
350(26):
2708 - 2710.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. J. Kereiakes
Adjunctive Pharmacotherapy before Percutaneous Coronary Intervention in Non-ST-Elevation Acute Coronary Syndromes: The Role of Modulating Inflammation
Circulation,
October 21, 2003;
108(90161):
III-22 - 27.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|